Purchase Order W911QY16P0050
Ended Awarded Last action
- Contract number
- W911QY16P0050
- Awardee
-
Abzyme Therapeutics LLC UEI H2MLEFWV36N6
- Awarding agency
-
ACC Aberdeen Proving Ground
Army Contracting Command, Department of Defense
- Obligated
- $99,988
Award facts
- Contract value 67% obligated
-
- $99,987.61 Current, with exercised options
- $149,964.61 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- Joint PEO Chemical and Biological Defense Acquisition Support Center, Department of Defense
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- PSC
- AJ11 General Science And Technology R&D Services; General Science And Technology; Basic Research
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 4 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Pottstown, PA 19464, USA
- Research
- SBIR Program Phase I Action
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $99,988 |
About this award
This federal contract award, valued at $149,964.61, was made by the Joint Program Executive Office for Chemical and Biological Defense, a U.S. Department of Defense organization, to Abzyme Therapeutics LLC, a small, minority-owned, for-profit limited liability company. The contract was awarded under the Small Business Innovation Research (SBIR) program, Phase I, and is a firm-fixed-price purchase order. The contract supports research and development work by Abzyme Therapeutics related to enhancing production of the HIV gp120 protein using camelid VHH antibodies. Abzyme Therapeutics has received multiple previous federal grants from the National Institutes of Health (NIH) to develop novel therapeutics, including for progressive multiple sclerosis and retinal neovascular diseases.
Quick answers
Who was awarded contract W911QY16P0050?
W911QY16P0050 was awarded to Abzyme Therapeutics LLC by ACC Aberdeen Proving Ground (Army Contracting Command) on December 23, 2015.
How much is contract W911QY16P0050 worth?
The government has obligated $99,988 on W911QY16P0050. Its potential value, with all options, is $149,965.
Which agency awarded contract W911QY16P0050?
ACC Aberdeen Proving Ground (Army Contracting Command) awarded W911QY16P0050, with funding from Joint PEO Chemical and Biological Defense (Acquisition Support Center).
Was contract W911QY16P0050 competed?
The extent of competition for W911QY16P0050 was full and open competition after exclusion of sources. The government received 4 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award